International Stem Cell Corp. (ISCO.OB) Announces Favorable Research Showing Potential of Parthenogenesis

QualityStocks would like to highlight International Stem Cell Corp. (OTCBB: ISCO). International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISC a unique leadership role in the field of regenerative cell therapy.

In the company’s news yesterday,

International Stem Cell Corp. voiced its favor of a recent announcement by researchers at Nationwide Children’s Hospital that shows the potential of parthenogenetic stem cells to treat genetic diseases such as Huntington’s disease, beta thalassemia or tuberous sclerosis.

In a scientific paper entitled, “Gene therapy by allele selection in a mouse model of beta-thalassemia,” researchers describe how they used a mouse model of an inherited blood disorder that shows parthenogenesis may have the ability to create “genetically clean” stem cells.

“We at ISCO are particularly pleased to note this animal model research into the potential of parthenogenetic stem cells since ISCO has created method for creating immortal human parthenogenetic stem cell (hpSC) lines. We are constantly seeking ways to use such technology to treat human diseases, and this announcement is a positive indication showing the potential of parthenogenetic stem cells to treat certain types of autosomal dominant diseases such as particular forms of beta thalassemia or even Huntington’s disease,” Dr. Andrey Semechkin, CEO of ISCO stated in the press release. “We expect that the transition from animal models to human therapy using parthenogenetic cells will continue to evolve as ISCO continues to conduct its own therapeutic research and to collaborate with researchers across the world to discover new ways to use parthenogenesis and parthenogenetic stem cells to cure human disease. We have great hope that animal research such as that just reported will open new doors to human therapy and look forward to making our human parthenogentic lines available for such therapies.”

The paper was published in the Journal of Clinical Investigation by a team of researchers from the Center for Molecular and Human Genetics (Nationwide Children’s Hospital, Columbus, OH), the University of Pennsylvania, the University of North Carolina and the University of Minnesota led by John McLaughlin Ph.D.

“ISCO is actively conducting research on the creation and application of differentiated derivatives of hpSC for therapeutic use,” Dr Semechkin stated. “Specifically, ISCO has initiated a number of pre-clinical animal studies utilizing both hepatocytes and separately retina pigment epithelium cells, derived from hpSC. ISCO’s scientists were also the first to demonstrate the ability of hpSC to differentiate into neural cells and to develop approaches to obtain stable lines of parthenogenetic neural cells. These achievements open up the opportunity to assess the efficacy and safety of using parthenogenetic stem cells as a source to create neural cells for the treatment of diseases such as Parkinson’s, Alzheimer’s, and other neurodegenerative disorders. The work presented by Dr. McLaughlin once again confirms ISCO’s unique position in the field of stem cell based therapies.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.